

1 March 2017

Omni Innovation: US Patent Notice of Allowance Received

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

US Patent - Notice of Allowance

The Company is pleased to announce that the core patent application covering Omni Innovation's pre-meal technology for people with diabetes and pre-diabetes has passed a major milestone in its trajectory to grant status in the USA.

The United States Patent and Trademark Office has issued a Notice of Allowance for a substantial block of claims in the Omni Innovation patent application. This means that there is a high likelihood of proceeding to a grant of the patent, with a formal notification of grant likely to be received within two months.

Most importantly, the broadest allowed claim covers a method for moderating blood glucose in people with diabetes or pre-diabetes. The method involves administering a pre-meal drink that contains protein and fibre and that has shearbanding flow characteristics. Provided that the drink formulation is shearbanding, a wide variety of proteins and plant-derived fibres are included in the claim.

The United States is considered to be the most challenging country in the world for obtaining grants of patent. It is also the largest market in the world for Omni Innovation's pre-meal diabetes technology. The Notice of Allowance indicates that the US examiner considers Omni Innovation's technology to be both new and non-obvious relative to all previously described blood glucose technologies.

The achievement of the above milestone will greatly protect Omni Innovation from "copy-cat" pre-meal formulations by a competitor and create a significant impediment to similar-style pre-meal formulations being developed by unauthorised third parties. The Company is continuing to progress discussions with potential distribution partners in the US and this decision will provide greater intellectual property security for those parties.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omni Innovation

Omni Innovation is a private Melbourne based medical and functional food R&D company. Omni Innovation have, and continue to develop clinically validated and evidence-based dietary interventions in the areas of type-2 diabetes, pre-diabetes, medical weight management to improve health and quality of life.

In 2016 a license to Symbion Ltd (EBOS Ltd) was granted for the distribution of Faulding® GlucoControl™ for the dietary management of type 2 diabetes and pre-diabetes for release to the Australian market under their fully owned Faulding® brand.

For more information, please visit www.omniinnovation.com.au